Industry
Reports
Healthcare
North America Pancreatic Cancer Therapeutics & Diagnostics Market - Segmented by ...
The North American pancreatic cancer market is expected to grow modestly from USD XX million in 2016 to USD XX million in 2021, at a CAGR of XX%.
Globally, pancreatic cancer is the 12th most common cancer in men and 11th most common cancer in women. Addiction to cigarettes and health history are considered to be the foremost reasons increasing the risk.
North America Pancreatic Cancer Therapeutics & Diagnostics Market-Market Dynamics
Pancreatic cancer is a major challenge in the United States, where 30,000 patients are diagnosed with the disease each year. The U.S. has the highest number of pancreatic cancer patients in the world. SEER estimates that there were 46,420 new pancreatic cancer cases chronicled in the US in 2014. It also estimated that 39,590 deaths occurred in the US in 2014 as a result of pancreatic cancer, constituting 6.8% of the total cancer deaths in the US.
Drivers
Some factors contributing to the growth of the market are:
Restraints
Some factors limiting the growth of the market are:
The North American pancreatic cancer therapeutics & diagnostic market is segmented based on the type of cancer into endocrine and exocrine cancers. By the type of treatment, the market is segmented into surgery, chemotherapy, radiation therapy and targeted therapy. By the major tests, the market has been segmented into biopsy, endoscopic ultrasound, laparoscopy and CT scan ERCP. On the basis of geography, the market has been segmented into the USA, Canada, and Mexico.
Some of the key players in the market are:
What the Report Offers
1. Introduction
1.1 Market Definition
1.2 Research Methodology
2. Executive Summary
3. Market Overview
3.1 Market Drivers
3.1.1 Large Number of Unmet Needs in the Disease
3.1.2 Increase in the Healthcare Expenditure
3.1.3 Increasing Concern across the Globe
3.2 Market Restraints
3.2.1 Inadequate Results after Treatment
3.2.2 Difficulties in Early Diagnosis
3.2.3 High Cost Associated with the Treatment
3.2.4 Low Success Rate in Clinical Trials for Cancer Drugs
3.3 Market Opportunities
3.4 Market Threats
4. Porter’s Five Force Analysis
4.1 Bargaining Power of Suppliers
4.2 Bargaining Power of Buyers
4.3 Degree of Competition
4.4 Threat of Substitution
4.5 Threat of New Entrants
5. Market Segmentation
5.1 North America Pancreatic Cancer Therapeutics & Diagnostic Market, by Cancer Type
5.1.1 Exocrine Cancers
5.1.1.1 Pancreatic Adenocarcinoma
5.1.1.2 Acinar Cell Carcinoma
5.1.1.3 Cystadenocarcinomas
5.1.1.4 Others
5.1.2 Endocrine Cancers (PanNETs)
5.1.2.1 Functional
5.1.2.2 Non-Functional
5.2 North America Pancreatic Cancer Therapeutics Market
5.2.1 Surgery
5.2.3 Radiation Therapy
5.2.3 Chemotherapy
5.2.4 Chemoradiation Therapy
5.2.5 Targeted Therapy
5.3 North America Pancreatic Cancer Diagnostics Market
5.3.1 ERCP
5.3.2 Confirmatory Needle biopsy
5.3.3 Endoscopic Ultrasound
5.3.4 Laparoscopy
5.3.5 CT Scan
5.3.6 PET Scan
5.4 North America Pancreatic Cancer Therapeutics Market, By Region
5.4.1 U.S
5.4.2 Canada
5.4.3 Mexico
6. Competitive Landscape
6.1 Mergers & Acquisitions
6.2 Agreements, Collaborations & Partnerships
6.3 New Product Launches
6.4 Recommendations to New Market Players
7. Company Profiles
7.1 Amgen, Inc.
7.2 Eli Lilly and Company
7.3 Celgene Corporation
7.4 Clovis Oncology, Inc.
7.5 Novartis AG
7.6 Threshold Pharmaceuticals, Inc.
7.7 Incyte Corp
7.8 Merrimack Pharmaceuticals Inc.
7.9 Roche Ltd
7.10 NewLink Genetics
8. Appendix
8.1. Abbreviations
8.2. Sources
8.3. Bibliography
8.4. Disclaimer
